DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20192913

Correlational study of interleukin-6 with albuminuria in type 2 diabetes mellitus

Ganga Prasad Vaishya, Granth Kumar, Vijayavarman V., Sanjeev Kumar Pandey, Arun Kumar, Kiran K.

Abstract


Background: Individuals with type 2 diabetes display features of low-grade inflammation. Mediators of inflammation such as IL-6 have been proposed to be involved in the events causing as well as progression of diabetes. Diabetic nephropathy is one of the commonest causes of chronic kidney failure throughout the world. Although diabetic nephropathy is traditionally considered a non-immune disease, accumulating evidence now indicates that immunologic and inflammatory mechanisms play a significant role in its development and progression.

Methods: This cross sectional study was conducted in the department of medicine, UPUMS, Saifai. The study was conducted from June 2018 to February 2019. A total of 80 type 2 diabetes patients were included in the study. After informed consent, patients were recruited. FBS, PPBS, HbA1C, 24 Hrs Urinary protein and interleukin-6 levels were measured. The data was analysed using SPSS 23. Pearson co relation co efficient was determined between IL -6, HbA1c and Urinary protein.

Result: A total of 80 type 2 diabetes patients were studied. The study subjects were divided into 3 groups based on the urinary protein level into normo-albuminuria, Micro- albuminuria and macro- albuminuria. FBS, PPBS, HBA1c, 24 Hrs Urinary protein and Interleukin – 6 were significantly associated with proteinuria (p<0.001). Urinary protein was positively correlated with IL-6 (R2=0.57, p<0.01). The blood glucose was positively correlated with IL-6 (R2=0.413, p-0.01).

Conclusion: Raised IL-6 levels in diabetics revealed the presence of inflammation. Our study showed positive correlation between IL-6, HBA1c and Urinary protein.

Keywords


Albuminuria, Diabetes, Interleukin-6

Full Text:

PDF

References


Kristiansen OP, Poulsen MT. Interleukin-6 and diabetes: the good, the bad, or the indifferent?. Diabetes. 2005;54(2):S114-24.

Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol. 2003;149:1-38.

Hotamisligil GS. The role of TNF alpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999;245:621-25.

Febbraio MA, Pedersen BK. Muscle derived interleukin-6: mechanisms for activation and possible biological roles. Faseb J. 2002;16:1335-47.

Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-801.

Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998;41:1241-8.

Crook M. Type 2 diabetes mellitus: a disease of the innate immune system? an update. Diabet Med. 2004;21:203-7.

Vestra DM, Mussap M, Gallina P. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16:S78-82.

Tuttle KR: Linking metabolism and immunology: Diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol. 2005;16:1537-38.

Mora C, Navarro JF. Inflammation and diabetic nephropathy. Curr Diab Rep. 2006;6:463-68.

Soni S, Mathur R, Shukla S. Diabetic Nephropathy and its Relation with Inflammatory Markers-IL6 and C-reactive protein: a cross sectional study. Ann Int Med Den Res. 2016;2(5):ME29-ME32.

Hasegawa G, Nakano K, Sawada M, et al. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 1991;40:1007-12.

Navarro JF, Mora C, Rivero A. Urinary protein excretion and serum tumor necrosis factor in diabetic patients with advanced renal failure: effects of pentoxifylline administration. Am J Kidney Dis. 1999;33:458-63.

Hurst SM, Wilkinson TS, McLoughlin RM, Jones S, Horiuchi S, Yamamoto N, et al. IL-6 and Its Soluble Receptor Orchestrate a Temporal Switch in the Pattern of Leukocyte Recruitment Seen during Acute Inflammation. Immunity. 2001;14:705-14.

Vozarova B, Weyer C, Hanson K, Tataranni PA, Bogardus C, Pratley RE. Circulating interleukin6 in relation to adiposity, insulin action, and insulin secretion. Obes Res. 2001;9:414-7.

Buchard K, Aaen K, Horn T, Damme J, Bendtzen K. Interleukin 6: a functional and structural in vitro modulator of beta-cells from islets of Langerhans. Autoimmunity. 1990;5:185-94.

Shimizu H, Sato N, Tanaka Y, Ohtani K, Fukatsu A, Mori M. Interleukin-6 stimulates insulin secretion in HIT-T 15 cells. Horm Metab Res. 1995;27:37-8.

Shimizu H, Ohtani K, Y Kato Y, Mori M. Interleukin-6 increases insulin secretion and preproinsulin mRNA expression via Ca2+ dependent mechanism. J Endocrinol. 2000;166:121-6.

Joshi SV, Tambwekar SR, Khadalia K, Dhar HL. Role of inflammatory marker interleukin 6 (il-6) and insulin in diabetes and diabetic neuropathy. Bombay Hosp J. 2008;50(3):466-71.